30-Day Readmissions in PA Pressure-Guided HF Care III Heart Failure Patients (CHAMPION ClinicalTrials.gov NCT00531661) trial, physicians who implemented pulmonary artery (PA) pressure-guided HF management using a wireless implantable hemodynamic monitoring system (CardioMEMS HF System; St Jude Medical, Inc, Atlanta, GA) were able to improve the HF management of patients when compared with guideline-directed standard of care HF management alone. The PA pressure-guided HF management group (treatment group) experienced a significant reduction in HF hospitalization rates and a greater reduction in PA pressures, had fewer patients hospitalized for HF, more days alive, and outside of the hospital for HF, and an improvement in quality of life when compared with guideline-directed standard of care HF management only (control group). 15, 16 Hospitalization rates were also reduced in the predetermined subgroup analysis of patients with HF and preserved EF. 17 What is lacking from the main CHAMPION Trial results is if hemodynamic-guided HF management was effective in older individuals and if this strategy impacted not only HF-related 30-day readmissions, but also all-cause readmissions. This report examines the impact PA pressure-guided HF management had on overall HF hospitalizations in this group with a focus on potentially preventable 30-day readmissions in the CHAMPION trial. The data address the potential role of ambulatory hemodynamic monitoring to help with requirements set forth by the Hospital Readmissions Reduction Program and other important healthcare quality improvement initiatives.
Methods

Patients
The CHAMPION trial enrolled 550 patients with New York Heart Association class III symptoms and hospitalization for HF within the prior 12 months. The detailed design and results of the study have been previously reported. 15, 16 Briefly, patients were enrolled regardless of left ventricular ejection fraction or pathogenesis and received all guideline-directed drug and device treatments for HF at optimal or best-tolerated stable doses before enrollment. All patients underwent baseline invasive hemodynamic evaluation with a right heart catheterization and were implanted with a PA pressure sensor before randomization.
Patients were randomly allocated in 1:1 fashion to either a treatment group in which physicians had access to PA pressure information from the hemodynamic monitoring system or to the control group in which physicians were blinded to this information. All patients remained in their randomized group until the last patient implanted with a PA pressure sensor completed 6 months of followup, which resulted in an average patient follow-up of 18 months. The current article reports a retrospective analysis of patients who were Medicare-eligible (≥65 years at the time of PA pressure sensor implantation), which was performed to assess the impact of PA pressure-guided HF management on hospitalizations and 30-day readmission rates. This age group was chosen to consistently apply Medicare methodology and allow direct comparison to US national statistics. The study protocol was reviewed and approved at the sites' Institutional Review Boards, and patients provided informed consent to be involved in the trial.
Hospitalization Classification and Analysis
The primary reason for all hospitalizations was prospectively adjudicated by an independent committee of HF Cardiologists. For the current evaluation, adjudicated hospitalizations were further characterized into 3 general categories: (1) index HF hospitalization (any HF hospitalization that did not occur within 30 days of a previous HF hospitalization), (2) readmission for HF (any HF hospitalization occurring within 30 days of an index HF hospitalization, and (3) all cause readmissions (all hospitalizations for any cause that occurred within 30 days of an index HF hospitalization). In alignment with the Center for Medicare & Medicaid Services criteria for reporting hospital readmission performance, 14, 18 hospitalizations during which a patient died, was transferred to another hospital, or was discharged against medical advice were excluded. A HF hospitalization occurring after 30 days from previous discharge was counted as a new index HF admission. Multiple rehospitalizations occurring within 30 days of an index HF hospitalization were not counted as 30-day readmissions or additional index HF admissions in accordance with the readmission measures guidance criteria. This analysis reports both all-cause and HF-related readmissions within 30 days of a qualifying index hospitalization.
To assess the estimated risk of readmission within 30 days from discharge in the treatment group, the validated HF 30-day readmission medical record logistic regression model 14, 18 includes 30 risk factors based on their statistical association with and clinical relevance to readmission. The medical records were reviewed to extract the relevant clinical data corresponding to 30 risk factors, including demographics, medical history, physical examination, and diagnostic parameters. The estimated regression coefficients from the reported model were applied to these patient characteristics, the model intercept term was added, and after transformation, summation over all admissions was performed to derive the estimated risk of readmission within 30 days from discharge in the treatment group, which was then compared with the observed 30-day readmission rate.
Hospitalization rates were also prospectively collected and analyzed for an average of 13 months after the randomized part of the trial as previously reported. 16 This important part of the trial opened access to pressures in the former control group patients for the first time and continued hemodynamic-guided care in the treatment group. Overall HF hospitalization rates in the Medicare-eligible population were evaluated and reported after transition to open access in the former control patients.
Medication Changes
Investigators recorded all medication changes and the reason for making the change. Reasons for changes in medications were classified as pressure based or signs and symptoms depending on what the investigator used to make the clinical decision. The total daily doses for each HF drug therapy class were calculated at baseline and after 6 months of follow-up for all patients in both groups. To assess total daily dose within a particular HF drug therapy class, standardization of the various HF drug therapies within that particular class was performed. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker doses were converted to enalapril equivalents, beta blocker doses were converted to carvedilol equivalents, aldosterone antagonist doses were converted to spironolactone equivalents, loop diuretics were converted to furosemide equivalents, and thiazide diuretics were converted to metolazone equivalents. For angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, and aldosterone antagonist, equivalency conversions were performed by (1) calculating the fraction of maximal total daily dose according to the total daily dose values from the American College of Cardiology Foundation/American Heart Association HF guidelines for each individual drug; (2) converting the fraction of maximal total daily dose to the appropriate drug class equivalent (eg, enalapril) by multiplying the fraction by the drug class equivalent's maximal total daily dose (eg, 40 mg). For patients who were on a particular HF drug therapy at baseline and at 6 months of follow-up, paired analyses of the change in total daily dose were performed. Within-group changes were calculated to determine what impact the different HF management strategies had on changes in total daily dose for each HF drug therapy.
After conversion to standard dose equivalents, all medication changes were then examined to identify when a dose change was an increase, decrease, or no change. Changes in medications which 30-Day Readmissions in PA Pressure-Guided HF Care resulted in equivalent drug dosing were classified as no change to consistently report all reported alterations in medical therapy. 19 
Utilization of Pulmonary Artery Pressure Monitoring Technology
To assess the patient experience with using the PA pressure monitoring technology, adherence to pressure uploads was analyzed. Daily compliance was defined as the percentage of study days outside the hospital with at least one reading uploaded, and weekly compliance was defined as the percentage of study weeks (7-day window) outside the hospital with at least one reading uploaded.
Statistical Analysis
Patient demographics, baseline hemodynamics, and medical histories were analyzed and compared between the treatment and control groups using a Wilcoxon Rank-Sum Test for continuous measures and a Fisher exact test for categorical measures. The number of outpatient medication changes after 6 months of follow-up were calculated and compared between the treatment and control group using the Wilcoxon rank-sum test. Hospitalization rates were analyzed using the Andersen-Gill extension of the Cox proportional hazards model. 20, 21 The validated HF 30-day readmission medical record logistic regression model 14, 18 was used to calculate readmission risk estimates. Data are summarized as frequencies and percentages for categorical variables. Continuous variables are presented as mean±standard deviation. For all statistical analysis, significance levels were 2-sided with a P value <0.05.
Results
Patient Characteristics
Two hundred forty-five of the 550 patients enrolled in the CHAMPION Trial (45%) were ≥65 years at the time of PA pressure sensor implantation (120 randomized to the treatment group and 125 to the control group). Patient demographics, baseline hemodynamics, and medical histories comparing the treatment and control groups are provided in Table 1 . Briefly, patients in this subgroup were predominantly white males with ischemic cardiomyopathy and a reduced ejection fraction. Frequency of comorbidities, including coronary artery disease, previous myocardial infarction, diabetes mellitus, and a history of atrial fibrillation were high and balanced in both groups. Implant right heart catheterization found elevated filling pressures in both groups at the time of sensor implantation. Treatment with American College of Cardiology/American Heart Association guideline-directed medical and device therapies, including angiotensin-converting enzyme/angiotensin receptor blockers, beta blockers, aldosterone antagonists, and cardiac resynchronization, before enrollment was present in high frequencies in both groups. Although an apparent imbalance in baseline left ventricular ejection fraction was seen between treatment and control patients, inclusion of left ventricular ejection fraction as a covariate in the hospitalization analysis model resulted in similar treatment effect point estimates in favor of PA pressure-guided HF management ( Table  I in the Data Supplement). Figure 1 illustrates patient flow through the follow-up, including reasons for exits.
Hospitalization Rates
The mean follow-up time in the Medicare-eligible subgroup was 515 days, resulting in a combined follow-up of over 350 patient-years. One-hundred seventy-seven HF hospitalizations occurred during the follow-up period, and 155 were determined to be eligible index HF hospitalizations for the 30-day readmissions analysis, with the remaining 22 HF hospitalizations being ineligible because they occurred within 30 days of a previous index HF hospitalization. Fifty-nine of the 155 index hospitalizations were rehospitalizations that occurred outside the 30-day window of the previous index event. In total, there were 44 all-cause readmissions with 21 (48%) because of HF.
The treatment group patients had a 49% lower (hazard ratio 0.51, 95% confidence interval 0.37-0.70; P<0.0001) HF hospitalization rate (60 HF hospitalizations, 0.34 events/ patient-year) compared with control group patients (117 HF hospitalizations, 0.67 events/patient-year; Figure 2 ). The treatment group had 58% less all-cause 30-day readmissions (13 readmissions, 0.07 events/patient-year) compared with the control group (31 readmissions, 0.18 events/patient-year; hazard ratio 0.42, 95% confidence interval 0.22-0.80; P=0.0080). This lower 30-day all-cause readmission rate was primarily the result of a 77% reduction in 30-day HF readmissions (4 HF readmissions, 0.02 events/patient-year) compared with the control group (17 HF readmissions, 0.10 events/patientyear; hazard ratio 0.23, 95% confidence interval 0.08-0.68; P=0.0080; Figure 2 ).
Seventy-two treatment Medicare-eligible patients and 63 control patients entered the open access part of the CHAMPION Trial and were followed for an average of 13 months. During this period, former control patients underwent PA pressure-guided HF management for the first time. HF hospitalization rate in the former control group patients was 47% lower than that during the randomized part of the trial (0.67 hosptializations/pt/y randomized part versus 0.35 hospitalizations/pt/y; P<0.005).
Risk-Stratified Readmission Ratio
Hospital records for the 56 index HF hospitalizations in the treatment group were reviewed, and the data corresponding to the risk factors from the medical record logistic regression model were recorded (Table 2 ). For each index HF hospitalization, the estimated regression coefficients from the reported model were applied, the model intercept term was added, and after transformation, summation over all admissions resulted in an estimated risk of readmission within 30 days from discharge of 31.4% (95% confidence interval 23.2%-40.9%; Table 3 ). There were 13 readmissions observed within 30 days from discharge for the 56 index HF hospitalizations in the treatment group, resulting in an observed 30-day readmission rate of 23.2%. The estimated readmission ratio for the treatment group-observed 30-day readmission rate relative to the estimated 30-day readmission risk was equal to 0.74.
Medical Management
The prevalence and total daily dose of baseline HF drug therapies are provided in Table 4 . Patients in both groups were well treated at baseline with guideline-directed medical therapies at mean doses higher than or similar to the doses achieved in previous landmark trials that were associated with a survival benefit. Through 6 months of randomized follow-up, 30-Day Readmissions in PA Pressure-Guided HF Care physicians titrated more HF therapies in the treatment group with access to PA pressure information ( Table 5 ). Significantly more medication changes were seen in the treatment group (2.3±2.0, n=279) compared with the control group (1.4±1.4, n=184; P<0.0001). Detailed evaluation of increases and decreases in each medication class is reported in Table 5 . Medication changes that did not result in effective difference in normalized drug dosing were not included in Table 5 , which accounts for the difference between total changes and the sum of increases and decreases. At the end of 6 months, the treatment group had significant uptitration of angiotensinconverting enzyme/angiotensin receptor blocker, beta blocker, and loop diuretic total daily doses with no changes in dose observed in the control group (Table 6 ).
Hospital Compare Database
Public reporting of readmissions occurring at US hospitals from July 2008 to June 2011 is available for analysis as part of the Hospital Compare Database. During this reporting time period, the 64 hospitals in the CHAMPION trial had an average excess readmission ratio of 0.99 in all Medicare patients discharged with a diagnosis of HF. Thus, the predicted number of readmissions that occurred at these hospitals was similar to the expected number of readmission for patients with similar clinical characteristics at an average hospital and is an indicator of adequate quality of care performance. For comparison with the findings from the CHAMPION trial, an estimated readmission ratio of 0.74 is an indicator of superior quality of care performance (Figure 3 ).
Utilization of Pulmonary Artery Pressure Monitoring Technology
Patient adherence to daily uploads using the PA pressure monitoring system was high at 93% for median daily compliance and 100% for median weekly compliance through 6 months of follow-up. Elderly patients comprising this subgroup integrated the technology into their daily routine similar to the experience observed for the entire CHAMPION trial cohort where 88% daily compliance and 100% weekly compliance was observed.
Discussion
The current analyses from the CHAMPION Trial examine several important gaps in the application of hemodynamic-guided HF management. Specifically, the study addresses several important questions, including the ability of Medicare-eligible patients to adhere to daily interact with new technology, and if this approach is effective in older individuals. Additionally, this study found that hemodynamic-guided HF management in Medicare patients effectively and significantly reduces the risks of being readmitted to the hospital in the 30 days after a HF hospitalization. These findings were associated with personalization of medical therapies based on individual filling pressures as suggested by both significantly more increases and decreases in HF medical therapy, particularly diuretics, in response to PA pressure information.
The CHAMPION trial specifically tested the hypothesis that active treatment of frequently assessed and remotely acquired filling pressures, primarily by altering or initiating diuretics or vasodilator therapies, effectively reduces recongestion, thus ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; CRT-D, cardiac resynchronization therapy with defibrillator; GDMT, guideline directed medical therapy; GFR, glomerular filtration rate; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; PVR, pulmonary vascular resistance; and PA, pulmonary artery. 30-Day Readmissions in PA Pressure-Guided HF Care significantly reducing hospitalization. It was unclear, however, if this strategy was reproducible in older patients, who stereotypically do not interact well with new technologies and are often underrepresented in clinical trials used to establish consensus management recommendations. Also, no information about timing of rehospitalizations was reported from the CHAMPION Trial. This is particularly germane to the problem of preventable readmissions that occur within 30 days of a previous HF index hospitalization. The current analysis supports the hypothesis that Medicare-eligible patients with HF are capable of interacting with new technology and derive significant benefit from a medical therapy strategy based on frequently measured PA pressures. This novel treatment strategy was compared with HF management using traditional tools, such as daily measured weights, symptom reporting, frequent encounters, biomarker assays, other device-based diagnostics, which were used in the control group of the trial and represent standard HF disease management. Not only were overall HF hospitalizations reduced in the treatment group, but the need to rehospitalize older patients 30 days after an index HF hospitalization was reduced by 58%. Clearly, investigators in the CHAMPION Trial acted on pressure information and reported more changes in HF drug therapy guided by PA pressure information in the treatment group. Interestingly, both increases and decreases of diuretic therapies occurred more often in the treatment group compared consistent with findings from the entire CHAMPION population. 19 This suggests that pressure information was used to personalize medication delivery for treatment group patients based on remotely obtained filling pressure information.
These observations are congruent with previous clinical trial experience, which found that currently used disease management strategies are insensitive in detecting filling pressure changes because even intense monitoring of daily weights and symptoms failed to reduce hospitalization risk. [21] [22] [23] Further complicating HF management using current tools is that most of them require face-to-face encounters to be performed. This is particularly important because most of the patient's life is outside the confines of clinic visits and face-to-face evaluations. The gold standard for volume assessment is the direct measurement of filling pressures, but this traditionally requires repeated invasive right heart catheterizations, making the Treatment (PA pressure monitoring) 30-Day Readmissions in PA Pressure-Guided HF Care approach impractical and costly. Excess volume exerts excess pressures, leading to worsening symptoms of congestion. The advent of new technology with the microelectromechanical sensor used in this study allowed a safe permanent implantation of a device to frequently measure filling pressures from the patient's home and guide HF medical management. Previous studies using implantable hemodynamic monitoring systems supported the hypothesis tested in the CHAMPION Trial, demonstrating that patients who persistently have high filling pressures are at high risk for hospitalization [24] [25] [26] and treatment, resulting in lower pressures, lower risk. Additionally, patients with progressive increases in filling pressures, detectable long before changes in daily weights or symptom development, are also at high hospitalization risks.
The present subgroup analysis demonstrated that pressureguided medical management of Medicare-eligible HF patients The model parameters and risk variables from the validated logistic regression model are provided. Hospital records for the 56 index HF hospitalizations in the treatment group were reviewed and data corresponding to the risk factors from the medical record logistic regression model were recorded (Treatment Group Profile). BUN indicates blood urea nitrogen; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; LVEF, left ventricular ejection fraction; and PTCA, percutaneous transluminal coronary angioplasty. 30-Day Readmissions in PA Pressure-Guided HF Care resulted in a 49% reduction in the need for HF hospitalization compared with patients cared for using traditional methods. Additionally, the elderly patients enrolled in the CHAMPION Trial were certainly tech-savvy because they volunteered for a clinical investigation and were more adherent to daily uploads than the overall cohort of patients. 15 These data suggest that clinical interventions that require technology interaction should not be withheld from this population based on stereotypic assumptions.
The findings are consistent with the overall experience observed in the total CHAMPION cohort. 15, 16 Overall hospitalization rates are concerning, but readmissions within 30 days of discharge are also important, potentially preventable events. In this regard, the Hospital Readmissions Reduction Program was created to encourage reduction of all-cause readmissions occurring within 30 days of index hospitalizations. The 3 conditions originally identified for this program include acute myocardial infarction, HF, and pneumonia, and Center for Medicare & Medicaid Services has now expanded the conditions to include chronic obstructive pulmonary disease and total hip/knee arthroplasty. Hospitals underperforming in this metric will incur a 3% penalty in the form of reduced Medicare base reimbursements for inpatient services for all diagnosis-related groups for fiscal year 2015. 12 Physicians and hospital administrators are now faced with the difficult task of providing high-quality, proactive care for an increasing HF patient population not only to reduce the rate of costly HF hospitalizations, but also to continue this highquality care during the hospitalization and extend it through 30 days after discharge. To date, currently available HF therapies and technologies have proven inadequate in solving this problem because HF hospitalizations and subsequent 30-day readmission rates remain unacceptably high.
Randomization in the CHAMPION trial is a form of risk standardization that increases the likelihood that clinically relevant characteristics are similar between the treatment and control groups. Within this framework, the need for hierarchical logistic regression modeling, as used by the Hospital Readmissions Reduction Program, is reduced because risk adjustment may be unnecessary in light of the balance achieved through the randomization process for both observed and unobserved patient characteristics. One important limitation of the medical record model derived from retrospective methods is that it can only adjust for observed patient characteristics that are recorded in the data set. Therefore, a comparison of the observed 30-day readmission rates between the treatment and control groups was also performed. There were 31 readmissions observed within 30 days from discharge for Interestingly, these findings from a randomized study are similar to results from the medical records model and suggest that the medical records model is an adequate proxy for estimating risk in this HF patient population. 27 Predictions about future incidence and prevalence of HF in the United States are worrisome. Currently estimated costs to Medicare for HF care were at $34.4 billion in 2010, most of which was incurred in hospitalizations. With increasing prevalence of HF, the predicted costs of this disorder are expected to exceed $95.1 billion by 2030. This assumes the same utilization of hospitalizations to treat decompensated HF. These data underscore the need for new and effective strategies to make HF disease management an outpatient process that prevents hospitalization rather than reacts to decompensation. The technology tested in the CHAMPION trial provides insight into ongoing HF pathophysiology to allow practitioners to maintain stability and avoid hospitalizations.
Limitations
It is important to note that the background quality of care at the 64 hospitals in the CHAMPION trial was representative of all US hospitals with similar excess readmission ratios and HF discharge volumes similar to national averages (see Figure 3 ). However, the patients enrolled in the CHAMPION Medication changes that did not result in a difference in normalized effective doses were not included, which is why the total number of medication changes do not equal the sum of the increases and decreases. Diuretic dosing was normalized to furosemide and metolazone equivalents, ACE/ARB to enalapril equivalent, nitrate to isosorbide mononitrate equivalent, β-blocker to carvedilol equivalent, and aldosterone antagonist to spironolactone equivalent. Diuretic dosing was normalized to furosemide and metolazone equivalents, ACE/ARB to enalapril equivalent, nitrate to isosorbide mononitrate equivalent, β-blocker to carvedilol equivalent, and aldosterone antagonist to spironolactone equivalent. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; and HF, heart failure.
*P value testing baseline dose to 6 mo dose using paired Wilcoxon Test within groups. 30-Day Readmissions in PA Pressure-Guided HF Care trial may not be representative of the average patient comprising the Hospital Compare Database, which includes patients at higher acuity, such as those in Hospice or nursing facilities along with lower risk ambulatory patients. In addition, the CHAMPION trial included less women and non-white patients than would be expected in the general HF population. The trial specifically focused on patients with New York Heart Association class III symptoms who were hospitalized in the previous year for HF, despite receiving drug and device treatments at optimal or best-tolerated stable doses before enrollment and were expected to complete the trial. This likely represents a portion of the patients included in the Hospital Compare database. Thus, it is not known whether the magnitude of benefit observed in the CHAMPION trial and the significant reductions in HF hospitalization rates and 30-day readmission rates obtained in the treatment group through PA pressure monitoring would be applicable to HF patients who are at different risk states.
Conclusions
HF management based on frequent assessment of PA pressures in Medicare-eligible patients is a safe and effective strategy to reduce hospitalizations in patients with persistent symptoms after previous HF hospitalization. Particularly important for this cohort is that pressure-guided strategy for HF management led to significantly more medication changes in the treatment group, which resulted in a substantial decrease in 30-day all-cause and HF readmissions. These results further underscore the value of frequently acquired PA pressures as a superior means to maintain stability and prevent decompensation compared with traditional management strategies. 28, 29 
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